home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

317 rows where filing_period = "second_quarter", filing_year = 2020 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 317 ✖

filing_year 1

  • 2020 · 317 ✖

filing_period 1

  • second_quarter · 317 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2458622 ALLERGAN USA, INC. 6d50b898-5265-4457-9302-c6012138cdb8 2T ALLERGAN USA, INC. 63837 ALLERGAN USA, INC. 2020 second_quarter PHA Supporting proposals to strengthen cGMP; encouraging full implementation and enforcement of the Drug Quality and Safety Act. Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office   230000 0 1 2020-05-13T14:51:32.380000-04:00
2459820 LEBLANC GOVERNMENT RELATIONS, LLC a68f2658-896e-49e3-817b-5d9f8a42f1e0 2T LEBLANC GOVERNMENT RELATIONS, LLC 400670003 CROSSROADS STRATEGIES ON BEHALF OF ALITHEON, INC. 2020 second_quarter PHA In support of Alitheon technology for pharmaceutical verification in difficult locations. Defense, Dept of (DOD),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),U.S. Agency for International Development (USAID)     0 1 2020-06-03T09:45:04.357000-04:00
2460537 JOHNSON MATTHEY INC. e7adfc09-0a36-4b72-93e6-c1123dd20f30 Q2 JOHNSON MATTHEY INC. 401104441 JOHNSON MATTHEY INC. 2020 second_quarter PHA H.R. 965 and S. 340, CREATES Act of 2019, provisions relating to improving the process by which generic drug manufacturers could obtain sufficient quantities of brand drug samples for testing thereby deterring practices that impede generic entry to the market. H.R. 938, BLOCKING Act of 2019, provisions relating to discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 3, Lower Drug Costs Now Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. H.R. 19, Lower Costs, More Cures Act of 2019, provisions relating to enhancing first generic drug manufacturers' 180-day exclusivity protections, process improvements and new FDA authority concerning generic drug manufacturers' access to reference samples from branded drug manufacturers, and discouraging parking of the 180-day exclusivity period for first generic drug manufacturers challenging pharmaceutical patents. S. 1895, Lower Health Care Costs Act of 2019, provisions relating to modifications to the exclusivity benefits afforded to first-to-file generic drug manufacturers. Environmental Protection Agency (EPA),HOUSE OF REPRESENTATIVES   30000 0 0 2020-07-01T08:10:50.653000-04:00
2460562 HCM STRATEGISTS 5787507a-b41f-45aa-838c-ae6530cb0dfa 2T HCM STRATEGISTS 400459263 ALLIANCE OF COMMUNITY HEALTH PLANS 2020 second_quarter PHA 2593, The Prescription Drug Pricing Reduction Act (PDPRA) of 2019 HR 3, The Elijah E. Cummings Lower Drug Costs Now Act       0 1 2020-07-01T09:39:02.153000-04:00
2460800 4C COMMUNICATIONS, INC. 30faec26-2935-4cd8-b831-952d72eed84e Q2 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2020 second_quarter PHA Discussion on pharmaceutical drug pricing; cost of pharmaceutical drugs in the Medicare Part D program HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-07-02T13:42:46.697000-04:00
2461045 THE KUTLER GROUP 62310649-dcbb-4a28-ab98-bd79e94f9f7f Q2 THE KUTLER GROUP 401103966 PRIME THERAPEUTICS 2020 second_quarter PHA drug pricing issues monitor Covid 19 legislation HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2020-07-03T11:31:25.557000-04:00
2461125 RED+BLUE STRATEGIES 34ba2265-c98f-4529-9a5a-13c69dba2614 Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2020 second_quarter PHA H.R. 1425 - The Patient Protection and Affordable Care Enhancement Act - Issues related to policies impacting the price of prescription medications. H.R. 6800 - The Heroes Act - Issues related to the role of pharmacy benefits and prescription medications in response to the COVID -19 pandemic. H.R. 748 - CARES Act -Implementation- Issues related to supporting the national work fighting COVID-19 and ensuring that medication is available during the COVID-19 crisis and beyond. H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting public and private healthcare programs and providers. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation- Issues related to supporting programs and institutions supporting during the current pandemic. HHS rules and regulations related to the cost of prescription drugs, including, but not limited to, limiting rebates in the Medicare and Medicaid prescription drug benefits. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-03T14:03:55.633000-04:00
2461148 RED+BLUE STRATEGIES dcd15576-6a83-4557-89c8-f2759ab38b59 Q2 RED+BLUE STRATEGIES 400693064 PEW CHARITABLE TRUSTS 2020 second_quarter PHA S. 6725 - The National Defense Authorization Act - Issues related to ensuring that there are antibiotics in the pipeline to ensure that our nation's troops are adequately protected from infection-related complications. H.R. 6800 - THe HEROES Act - Issues related to continuing the fight against SUD and opioid addiction in the time of COVID. Issues related to ensuring that there were new, effective antibiotics in the pipeline to treat secondary infections due to hospitalizations for COVID. Issues related to HIT as a tool during the pandemic. H.R. 748 - CARES Act - Implementation - Issues related to supporting the national work fighting COVID-19 and ensuring that antibiotics are available during the COVID-19 crisis and beyond and OTC monograph reform is address to enhance patient safety. H.R. 6201 - Families First Coronavirus Response Act - Implementation- Issues related to ensuring that the federal government is best supporting the public good with a focus on ensuring there is a strong antibiotics pipeline to fight secondary infections and over the counter medications are safe and secure. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act of 2020 -Implementation - Issues related to supporting programs and institutions supporting during the current pandemic. S. 1712/H.R. 4100 - THe DISARM Act - Support for ensuring that there are sufficient antibiotics in the pipeline to meet the national need. H.R. 2482 - The Mainstreaming Addiction Treatment Act of 2019 - Support for policies increasing the ability to access MAT to treat addiction. Issues related to creating a listing mechanism for dietary supplements. Issues related to the implementation on the SUPPORT Act (P.L. 115-271) HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-03T14:57:05.807000-04:00
2461156 RED+BLUE STRATEGIES c785f7de-5fb6-465c-9d6b-bc371e139be7 Q2 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2020 second_quarter PHA Issues focused on Made in America and the importance of keeping Rx-related jobs and manufacturing in the United States. H.R. 6800 - The HEROES Act - Issues related to lowering costs of prescription drugs for Americans. H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act - Implementation- Issues related the COVID-19 that impacts small businesses as well as need for cancer medications for patients. H.R. 6201 - Families First Coronavirus Response Act -Implementation - Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 748 - The CARES Act - Implementation- Issues related to insuring the safety of American families, workers and health providers and the role biosimilars can play. Additionally, policies related to supporting small businesses. H.R. 1865 - Further Consolidated Appropriations Act, 2020 - Implementation - Support for passage of the CREATES Act and other issues that support the country's new biosimilars market place. H.R. 3 - Lower Drug Costs Now Act - Issues related to enhancing the development and success of the American biosimilars marketplace. S. 1895 - The Lowering Health Care Costs Act - provisions related to creating a fair playing field for biosimilars in the United States. Issues related to improving and expanding the biosimilars marketplace through policies that will create a more even playing field for biosimilars in the overall prescription drug marketplace in the United States. Areas of focus include policies regarding patent law, public and private reimbursement and FDA interchangeability standards. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-03T15:47:09.990000-04:00
2461407 ISEMAN & ASSOCIATES LLC bf3759e8-2a87-4dc6-91d2-a99e667e0f1d Q2 ISEMAN & ASSOCIATES LLC 401103582 TICHENOR VENTURES, LLC 2020 second_quarter PHA Monitoring biotech legislation; prescription drug prices HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2020-07-06T14:03:24.150000-04:00
2461623 AMERICAN COLLEGE OF CLINICAL PHARMACY 370193c2-281b-4443-827d-007bdb2d6238 Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2020 second_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2020-07-07T04:42:14.807000-04:00
2461663 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 8c0747c5-2daa-4160-aa22-0d50334767f3 Q2 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2020 second_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of health care. Issues related to continuation of prescription drug access and testing during COVID crisis. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2020-07-07T08:38:32.213000-04:00
2461804 HOLLAND & KNIGHT LLP d5656b5c-cf96-4665-9f86-5ef6f35db644 Q2 HOLLAND & KNIGHT LLP 18466 TEVA PHARMACEUTICALS USA, INC. 2020 second_quarter PHA Drug pricing; Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (H.R. 6074); Families First Coronavirus Response Act (H.R. 6201); Coronavirus Aid, Relief, and Economic Security (CARES) Act (H.R. 748); Global supply chain issues; National Defense Authorization Act. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-07-07T13:26:04.840000-04:00
2462244 BOYDEN GRAY & ASSOCIATES PLLC 53f54704-be11-403b-8066-12863b8169a5 Q2 BOYDEN GRAY & ASSOCIATES PLLC 400748240 ILLINOIS CORN GROWERS ASSOCIATION 2020 second_quarter PHA Regulation of alcohol for use in hand sanitizer Agriculture, Dept of (USDA),Office of Management & Budget (OMB),SENATE 80000   0 0 2020-07-08T09:35:01.280000-04:00
2462246 PARAGON BIOSCIENCES, LLC e90a1bb7-8808-4976-a9ee-537e1a5381ba Q2 PARAGON BIOSCIENCES, LLC 401105338 PARAGON BIOSCIENCES, LLC 2020 second_quarter PHA Issues related to public and private investment in biosciences and R&D HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2020-07-08T09:38:02.450000-04:00
2462389 THORSEN FRENCH ADVOCACY LLC 36b89b9a-edcd-4c84-8c08-51dbd23a5b61 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 HEALTHCARE DISTRIBUTION ALLIANCE 2020 second_quarter PHA General issues related to prescription drug abuse. Issues related to pharmaceutical market value. Prescription drug importation. Issues related to regulation of prescription opioid medication. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-08T11:53:36.857000-04:00
2462396 THORSEN FRENCH ADVOCACY LLC 970fce76-6efc-423b-add3-5fc1c27bc125 Q2 THORSEN FRENCH ADVOCACY LLC 400599826 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2020 second_quarter PHA Issues related to pharmaceutical market value. Global supply chain. Proposed Notice of Benefit and Payment Parameters (NBPP) Rule for 2021. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-07-08T11:57:41.750000-04:00
2462426 WAKEFERN FOOD CORP. e85d5b0d-eb02-4971-bca4-fa76088ccbc9 Q2 WAKEFERN FOOD CORP. 400588798 WAKEFERN FOOD CORP. 2020 second_quarter PHA S.988/HR.803 Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, all provisions related to Direct and Indirect Remuneration (DIR) fees. HOUSE OF REPRESENTATIVES,SENATE   10000 0 0 2020-07-08T12:39:59.153000-04:00
2462588 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 73061ec1-61c2-4e04-8dda-32f2807848a6 Q2 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2020 second_quarter PHA Discussed role of contract development & manufacturing organizations in COVID-19 therapeutics and vaccines, and potential solutions for drug shortages, including those posed by pandemic sitiuations, in addition to general education about role of bio/pharmaceutical contract manufacturing organizations and development service providers. HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2020-07-08T16:28:15.767000-04:00
2462959 RUBICON ADVISORS, LLC d16ffdc5-c9c5-4148-b3d5-68caf0c4dcad Q2 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2020 second_quarter PHA Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA) HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2020-07-09T13:09:52.113000-04:00
2462964 RUBICON ADVISORS, LLC c7a2750e-bc23-4d14-88e8-b6d562e0dac8 Q2 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2020 second_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 45000   0 0 2020-07-09T13:13:57.197000-04:00
2462973 RUBICON ADVISORS, LLC 972d6bb1-9b35-4f17-b328-f3d98c20172a Q2 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2020 second_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 37500   0 0 2020-07-09T13:22:04.457000-04:00
2463006 RUBICON ADVISORS, LLC 599b10b9-e8ea-4173-83e0-2ff999ff0a63 Q2 RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2020 second_quarter PHA Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 60000   0 0 2020-07-09T13:33:21.667000-04:00
2463030 RUBICON ADVISORS, LLC 53e5cd54-a05e-4a99-a4a9-fed934e2b5e9 Q2 RUBICON ADVISORS, LLC 315091 AVET PHARMACEUTICALS 2020 second_quarter PHA GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES 30000   0 0 2020-07-09T13:54:47.707000-04:00
2463367 AMERICAN PHARMACISTS ASSOCIATION fa6dfd70-58b1-4fda-9ae3-31f9a7ea52ea Q2 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2020 second_quarter PHA H.R. 789 - To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. H.R. 803 - This bill prohibits Medicare prescription drug plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. (A "clean claim" is a Medicare claim that is free of defects such as incomplete documentation.) H.R. 1034 - Phair Pricing Act of 2019; To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program S. 640 - To amend title XVIII of the Social Security Act to require pharmacy-negotiated price concessions to be included in negotiated prices at the point-of-sale under part D of the Medicare program, and for other purposes. S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers. S. 476 - Creating Transparency to Have Drug Rebates Unlocked (C-Thru) Act of 2019 - To amend titles XI and XVIII of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers. H.R. 3 Lower Drug Costs Now Act of 2019-To establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees, and for other purposes. S.2543 Prescription Drug Pricing Reduction Act of 2019 -To amend titles XI, XVIII, and XIX of the Social Security Act to lower prescription drug prices in the Medicare and Medicaid programs, to improve transparency related to pharmaceutical prices and transactions, to lower patients' out-of-pocket costs, and to ensure accountability to taxpayers, and for other purposes. HR 5304 PBM Transparency in Prescription Drug Cost Act - To amend t… HOUSE OF REPRESENTATIVES,SENATE   34000 0 0 2020-07-10T12:21:58.880000-04:00
2463520 PANNONE LOPES DEVEREAUX & O'GARA LLC b4016690-8adf-47a3-847a-309dae497f03 Q2 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2020 second_quarter PHA Prescription drug pricing.   9000   0 0 2020-07-10T15:16:24.177000-04:00
2463763 REPUBLIC CONSULTING, LLC e08a0d9b-0096-4f30-9d8f-f3969077cd59 Q2 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2020 second_quarter PHA Monitor Data and Science Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-11T12:50:40.997000-04:00
2463945 FLYNN & ASSOCIATES, INC. 585fd953-351e-403d-87b3-a02ae9d7a519 Q2 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2020 second_quarter PHA ACA Stabilization - Drug Pricing Drug importation from Canada HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-13T09:22:59.507000-04:00
2463991 INDEPENDENT PHARMACY COOPERATIVE 304cc4d5-0cea-4583-b746-55318673c8a9 Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2020 second_quarter PHA The Prescription Drug Pricing Reduction Act S. 2543-IPC supports. Improving Transparency and Accuracy in Medicare Part D Spending Act S.988/ HR 803-IPC supports all pharmacy price concessions be reflected at the point-of-sale. Support regulations that would eliminate pharmacy DIR. IPC supports Pharmacists as providers under Medicare Part B IPC supports Pharmacists as Imunnizers First Families Coronavirus Response Act 2020. IPC supports The Coronavirus Aid, Relief and Economic Security Act 2020. IPC supports Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE   30000 0 0 2020-07-13T10:40:53.477000-04:00
2464219 BROWN & FORTUNATO, P.C. 92ef6059-076e-42aa-ba9e-4cb26bc5d333 Q2 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2020 second_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program. Issues related to H.R. 4945 - Safeguarding Medicare Access to Respiratory Therapy Act of 2019; H.R. 1865 - Further Consolidated Appropriations Act, 2020; H.R. 748 - CARES Act; H.R. 6201 - Family First Coronavirus Response Act. Issues related to H.R. 6218 and S. 3457 - The Preserving Medicare Access to Home Infusion Act. Centers For Medicare and Medicaid Services (CMS) 20000   0 0 2020-07-13T14:08:05.557000-04:00
2464310 TAUZIN STRATEGIC NETWORKS a0179fb6-aad2-40a6-aaf9-dc3c1cabbdbe Q2 TAUZIN STRATEGIC NETWORKS 400786367 CAPTURERX 2020 second_quarter PHA Issues related to the 340b program HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-13T14:58:34.520000-04:00
2464334 POLSINELLI PC 6a2e6451-9d09-4cb8-afca-b5da01a0dc23 Q2 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2020 second_quarter PHA S. 2543, Prescription Drug Pricing Reduction Act S. 1895, Lower Health Care Costs Act H.R. 3, Lower Drug Costs Now Act Coronavirus stimulus legislation Review of Administration drug pricing policies HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-07-13T15:13:43.367000-04:00
2464345 CRISPR THERAPEUTICS, INC. ce668b1f-1cef-4b94-ad12-59c7702ab495 Q2 CRISPR THERAPEUTICS, INC. 401105184 CRISPR THERAPEUTICS, INC. 2020 second_quarter PHA Reimbursement for cell and gene therapies. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE   80000 0 0 2020-07-13T15:25:46.660000-04:00
2464827 NATIONAL ASSOCIATION OF CHAIN DRUG STORES a776c6e3-eebd-4245-8b5d-1091eb11959f Q2 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 26672 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2020 second_quarter PHA H.R. 1614 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S. 724 A bill to amend the Controlled Substances Act to establish additional registration requirements for prescribers of opioids, and for other purposes; John S. McCain Opioid Addiction Prevention Act S.340 CREATES Act of 2019 H.R. 985 FAST Generics Act of 2019 S.640 Phair Pricing Act of 2019 S. 97 Affordable and Safe Prescription Drug Importation Act S. 61 Safe and Affordable Drugs from Canada Act of 2019 H.R. 1034 Phair Pricing Act of 2019 H.R. 965 CREATES Act of 2019 H.R. 1478 Affordable Insulin Act of 2019 H.R. 447 Affordable and Safe Prescription Drug Importation Act H.R. 1499 Protecting Consumer Access to Generic Drugs Act H.R. 3417 The Beneficiary Education Tools, Telehealth, and Extenders Re-authorization Act of 2019 H.R. 2296 Fair Accountability and Innovative Research Drug Pricing (FAIR Drug Pricing) Act of 2019 H.R. 1607 Fairness to Pet Owners Act H.R. 3379 Priced Relief, Innovation, and Competition for Essential Drugs (PRICED) Act H.R. 478 Safe and Affordable Drugs from Canada Act of 2019 H.R. 3 Lower Drug Costs Now Act of 2019 H.R. 275 Medicare Prescription Drug Price Negotiation Act of 2019 H.R. 448 Medicare Drug Price Negotiation Act H.R. 1046 Medicare Negotiation and Competitive Licensing Act of 2019 H.R. 5304 PBM Transparency in Prescription Drug Costs Act H.R. 5172 NOPAIN Act S. 2543 Prescription Drug Pricing Reduction Act of 2019 S. Rept. 116-120 Prescription Drug Pricing Reduction Act of 2019 S. 2247 Phair Relief Act of 2019 S. 3070 Preventing Pill Mills Through Data Sharing Act H.R. 3055 Further Continuing Appropriations Act, 2020, and Further Health Extenders Act of 2019 H.R. 19 Lower Costs, More Cures Act on 2019 S. 3129 Lower Costs, More Cures Act on 2019 H.R. 748 Coronavirus Aid, Relief, and Economic Security Act or the CARES Act H.R. 6573 Help our Heroe… HOUSE OF REPRESENTATIVES,SENATE   700000 0 0 2020-07-14T10:56:59.123000-04:00
2464856 LUPIN PHARMACEUTICALS INC 2d3ce1d7-78ee-4926-a299-44bc0e419ebf Q2 LUPIN PHARMACEUTICALS INC 401104766 LUPIN PHARMACEUTICALS INC 2020 second_quarter PHA Not applicable this quarter. HOUSE OF REPRESENTATIVES,SENATE,U.S. Agency for International Development (USAID),U.S. Trade Representative (USTR)   236935 0 0 2020-07-14T11:24:07.880000-04:00
2464878 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 218f2d1b-8736-4a99-aac6-4e674989b80f Q2 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 312496 CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 2020 second_quarter PHA Drug pricing, 340B for children's hospitals Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office   40560 0 0 2020-07-14T11:37:14.437000-04:00
2465093 TODD STRATEGY GROUP af2398d3-c78c-4211-b8f1-e9d341f40fae Q2 TODD STRATEGY GROUP 401103321 ALKERMES, INC. 2020 second_quarter PHA Prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-14T13:42:16.427000-04:00
2465138 TODD STRATEGY GROUP 98c0729c-5668-43ef-a1c1-78522e5f2d6e Q2 TODD STRATEGY GROUP 401103321 ASTRAZENECA PHARMACEUTICALS LP 2020 second_quarter PHA Drug pricing. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-14T14:06:27.593000-04:00
2465142 TODD STRATEGY GROUP 2f538d50-a3c7-4bb5-9121-8025ba6cf239 Q2 TODD STRATEGY GROUP 401103321 BAYER CORPORATION 2020 second_quarter PHA Drug pricing. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-14T14:08:29.463000-04:00
2465153 TODD STRATEGY GROUP c1a592a0-0e06-4b64-b235-426f0799e858 Q2 TODD STRATEGY GROUP 401103321 BIOTECHNOLOGY INNOVATION ORGANIZATION 2020 second_quarter PHA Drug Pricing and Access. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-14T14:13:32.870000-04:00
2465154 TODD STRATEGY GROUP 89dfed3b-ca7c-476d-a5f2-0e3e2187fbaa Q2 TODD STRATEGY GROUP 401103321 CAREDX, INC. 2020 second_quarter PHA Coverage of immunosuppressive drugs. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 40000   0 0 2020-07-14T14:14:33.337000-04:00
2465160 TODD STRATEGY GROUP fdefb180-2ddb-46d0-9194-44027169ffb3 Q2 TODD STRATEGY GROUP 401103321 EMD SERONO INC. 2020 second_quarter PHA Drug pricing policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-14T14:16:36.577000-04:00
2465172 MEHLMAN CONSULTING, INC. 03eb0f84-9f41-409b-b282-96afee9f0446 2T MEHLMAN CONSULTING, INC. 284950 FOOD ALLERGY RESEARCH & EDUCATION (FARE) 2020 second_quarter PHA Labeling of allergens. HOUSE OF REPRESENTATIVES,SENATE 10000   0 1 2020-07-14T14:25:42.157000-04:00
2465224 TODD STRATEGY GROUP 043333dd-e202-4f1c-b612-3ddf61c0ed12 Q2 TODD STRATEGY GROUP 401103321 GENENTECH, INC. 2020 second_quarter PHA Prescription drug payment reform. Supply chain. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-14T14:40:56.667000-04:00
2465271 TODD STRATEGY GROUP ac464d07-0c09-407a-8f4e-c30648b56fa5 Q2 TODD STRATEGY GROUP 401103321 MERCK & CO., INC. 2020 second_quarter PHA Drug Pricing. S.1712/H.R.4100: DISARM Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-07-14T14:58:15.973000-04:00
2465290 TODD STRATEGY GROUP 3643df4f-422a-40b3-99c8-865a8448ff5f Q2 TODD STRATEGY GROUP 401103321 NOVARTIS, INC. 2020 second_quarter PHA Drug Pricing. Supply Chain. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-07-14T15:02:22.297000-04:00
2465299 TODD STRATEGY GROUP 6d2e4576-9efc-49a8-84a9-00844a9d1502 Q2 TODD STRATEGY GROUP 401103321 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2020 second_quarter PHA Drug Pricing and Access. Pharmaceutical Supply Chain. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-14T15:04:26.083000-04:00
2465306 MCDERMOTT+ LLC 4e1c1a70-03c4-446f-b6ef-e12d24d5c23a Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2020 second_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-14T15:07:28.920000-04:00
2465313 TODD STRATEGY GROUP be7de892-ef9e-4fde-adb6-1044af9142ef Q2 TODD STRATEGY GROUP 401103321 US WORLDMEDS, LLC 2020 second_quarter PHA Opioid Use Disorder Treatment Policy. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-07-14T15:10:32.153000-04:00
2465488 TODD STRATEGY GROUP 2ee734f1-f16c-41ae-9fb7-1ef4b45cc608 2A TODD STRATEGY GROUP 401103321 NOVARTIS, INC. 2020 second_quarter PHA Drug Pricing. Supply Chain. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-14T16:50:27.757000-04:00
2465494 TODD STRATEGY GROUP 93bacfe0-5720-47ae-bea9-62f88fc6e25a 2A TODD STRATEGY GROUP 401103321 MERCK & CO., INC. 2020 second_quarter PHA Drug Pricing. S.1712/H.R.4100: DISARM Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-14T16:53:29.587000-04:00
2465850 WINNING STRATEGIES WASHINGTON b43efa7c-6cd5-43a1-b394-cc1ea7e5b51e Q2 WINNING STRATEGIES WASHINGTON 50796 KALEO 2020 second_quarter PHA Pharmaceutical drug development, including epinephrine for anaphlylaxis; drug access and affordability issues Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-07-15T10:48:06.507000-04:00
2466097 WAXMAN STRATEGIES 8a568a99-8364-4064-9c65-e146a273d44a Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2020 second_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-15T11:43:02.520000-04:00
2466188 GREATER NEW YORK HOSPITAL ASSOCIATION 3449f9d2-40cf-4aca-bf79-a90f858d0a6a Q2 GREATER NEW YORK HOSPITAL ASSOCIATION 16830 GREATER NEW YORK HOSPITAL ASSOCIATION 2020 second_quarter PHA Discuss issues related to group purchasing organizations (GPOs) with Congressional staff and members. Discuss several pieces of legislation with Congressional staff including: the CREATES Act (H.R. 965/S. 340) (support), the Fast Access for Safe & Timely Generics Act (H.R. 985) (support), the Protecting Consumer Access to Generic Drugs Act (H.R. 1499) (support), the Fair and Immediate Release of Generic Drugs Act (H.R. 1506) (support), the Orange Book Transparency Act (H.R. 1503) (support), the Purple Book Continuity Act (H.R. 1520) (support), and the Bringing Low-Cost Options and Competition While Keeping Incentives for New Generics Act (H.R. 938) (support). Discuss the METRIC Act (H.R. 2296) with Congressional staff. Discuss legislation to address drug shortages with Congressional staff and members, the MEDS Act (S. 2373) (support), advocate for its inclusion in the CARES Act (H.R. 748). Discuss the Prescription Drug Pricing Reduction Act of 2019 (S. 2543) with Congressional staff and committee staff. Discuss Lower Drug Costs Now Act (H.R.3) with Congressional staff. Discuss drug shortages related to the COVID-19 crisis with Congressional and Administration staff. Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Defense, Dept of (DOD),Executive Office of the President (EOP),Federal Bureau of Investigation (FBI),Federal Emergency Management Agency (FEMA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),President of the U.S.,SENATE,Small Business Administration (SBA),Substance Abuse & Mental Health Services Administration (SAMHSA),White House Office   570000 0 0 2020-07-15T12:07:24.617000-04:00
2466204 TODD STRATEGY GROUP 86ed0d0c-6712-4d7e-b188-85eb8f2974b8 2A TODD STRATEGY GROUP 401103321 MERCK & CO., INC. 2020 second_quarter PHA Drug Pricing. S.1712/H.R.4100: DISARM Act of 2019. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-07-15T12:16:26.637000-04:00
2466212 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 44d0dc66-83d5-4ff3-b36c-bc9609ebb9d1 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2020 second_quarter PHA Pseudoephedrine -- Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient and oppose PSE restrictions such as a prescription requirement (no bill number). Mandatory recall authority of the FDA Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines. H.R.3164 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 S.930 - Allowing Greater Access to Safe and Effective Contraception Act S.1847/H.R. 3296 - Affordability is Access Act S.2522 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 H.R.6058 - SHOP SAFE Act of 2020 S.3431 - INFORM Consumers Act Legislation to increase domestic production of pharmaceuticals and the domestic supply chain. H.R. 6395 - National Defense Authorization Act for Fiscal Year 2021 S.4049 - National Defense Authorization Act for Fiscal Year 2021 Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,Vice President of the U.S.   128000 0 0 2020-07-15T12:18:27.303000-04:00
2466409 MEHLMAN CONSULTING, INC. 61d5e9f9-4e58-4c87-8307-b3da0acf0ccf Q2 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2020 second_quarter PHA S. 1895 - Lower Health Care Costs Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 110000   0 0 2020-07-15T13:33:18.350000-04:00
2466899 PUBLIC CITIZEN 9b1044e2-1099-488f-9a30-52c831f0a010 Q2 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2020 second_quarter PHA Access to coronavirus treatments and vaccines, COVID-19 medicine pricing and access, COVID-19 Emergency manufacturing act, transparency for federally support COVID R&D, Pharmaceuticals and antitrust Consumer Product Safety Commission (CPSC),HOUSE OF REPRESENTATIVES,Securities & Exchange Commission (SEC),SENATE,White House Office   110000 0 0 2020-07-15T16:15:19.427000-04:00
2467108 MEHLMAN CONSULTING, INC. e337b789-019f-49f1-bed6-f1949b818dc8 Q2 MEHLMAN CONSULTING, INC. 284950 BLUE SHIELD OF CALIFORNIA 2020 second_quarter PHA Prescription drug pricing. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-15T18:13:24.603000-04:00
2467115 LUNGREN LOPINA LLC 175067de-9e50-4fb5-8e80-be44317a7487 Q2 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2020 second_quarter PHA Fair treatment for US based pharmaceutical ingredients Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-07-15T18:16:26.827000-04:00
2467142 MEHLMAN CONSULTING, INC. 852a4369-0347-47cc-bc7d-56ad78f140e1 Q2 MEHLMAN CONSULTING, INC. 284950 AARP, INC. 2020 second_quarter PHA S.1895 - Lower Health Care Costs Act including issues relating to drug pricing Older Americans Reauthorization Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019. House prescription drug price transparency legislation. HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of 50000   0 0 2020-07-15T18:54:36.670000-04:00
2467173 TRINITY HEALTH a5111f27-5b0a-4a2e-919c-94faefc7e628 Q2 TRINITY HEALTH 24910 TRINITY HEALTH 2020 second_quarter PHA S 4160 340B Enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the public health service act prior to the COVID-19 public health emergency to temporarily maintain eligibility for program Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   200000 0 0 2020-07-15T20:03:46.307000-04:00
2467185 MEHLMAN CONSULTING, INC. 41bed9f3-d4dc-4b6e-8c1c-4cffaf72bef4 Q2 MEHLMAN CONSULTING, INC. 284950 AMERICA'S HEALTH INSURANCE PLANS 2020 second_quarter PHA Prescription drug pricing H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2020-07-15T20:06:47.400000-04:00
2467200 MEHLMAN CONSULTING, INC. d030d77f-55ae-440f-a478-a6a343150d37 Q2 MEHLMAN CONSULTING, INC. 284950 ASSOCIATION OF ACCESSIBLE MEDICINES 2020 second_quarter PHA Medicaid and Medicare drug pricing. Prescription drug pricing. S.1895 - Lower Health Care Costs Act. H.R. 938 - BLOCKING Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-15T20:15:50.177000-04:00
2467342 HOLLAND & KNIGHT LLP 708d46f0-595d-4194-817c-d3821e3a5c0d Q2 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2020 second_quarter PHA Drug shortages, formulary tiering, National Defense Authorization Act (NDAA), biosimilar uptake, the consumer price index, generic drugs. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-16T08:01:29.370000-04:00
2467712 KOUNTOUPES DENHAM CARR & REID, LLC 039b73ec-f5e7-443a-ada7-88ee682eb451 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2020 second_quarter PHA Policy matters related to generic pharmaceuticals and biosimilars, including H. R. 985, the FAST Generics Act of 2019. H. R. 1499, the Protecting Consumer Access to Generic Drugs Act of 2019, and H. R. 938, the BLOCKING Act of 2019. Changes to the Risk Evaluation and Mitigation Strategies (REMS) program. Reimbursement rate for biosimilars. S. 1895, the Lower Health Care Costs Act, S.2543, The Prescription Drug Pricing Reduction Act, and H. R. 3,The Lower Drug Costs Now Act. H. R. 1865. Issues related to the implementation of H. R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including supply chain issues for generic medicines. Issues related to H.R.6395 and S.4049, National Defense Authorization Act for Fiscal Year 2021, including pharmaceutical supply chain provisions. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT),Vice President of the U.S. 60000   0 0 2020-07-16T10:43:24.703000-04:00
2467947 TRAVERE THERAPEUTICS 1348a79c-aa7b-4bee-9edc-6776bdee273b Q2 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2020 second_quarter PHA H.R. 1781, Payment Commission Data Act; H.R. 1503, Orange Book Transparency Act of 2019; H.R. 1520, Purple Book Continuity Act of 2019; H.R. 965 and S. 340, the CREATES Act; H.R. 2113, STAR Act; S. 474, SPIKE Act/Wyden; S. 1391, FAIR Drug Pricing Act; S. 1895, Lower Health Care Costs Act of 2019; H.R. 2296, FAIR/More Efficient Tools to Realize Information for Consumers Act; H.R. 987, Strengthening Health Care and Lowering Prescription Drug Costs Act; H.R. 3, Lower Drug Costs Now Act; H.R. 19, Lower Costs More Cures Act and related legislation Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   150000 0 0 2020-07-16T11:28:25.487000-04:00
2468086 TWENTY-FIRST CENTURY GROUP, INC. cc8bd250-45e7-4827-b5e9-16e93ae89954 Q2 TWENTY-FIRST CENTURY GROUP, INC. 38687 CARDINAL HEALTH, INC. 2020 second_quarter PHA Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response;and the healthcare supply chain. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-07-16T11:51:04.003000-04:00
2468350 SUMMIT PUBLIC AFFAIRS 5b550962-4f81-4c53-9ec9-1d8f6a56d127 Q2 SUMMIT PUBLIC AFFAIRS 401105467 VANDA PHARMACEUTICALS INC. 2020 second_quarter PHA Issues affecting the pharmaceutical industry, including the prescription drug approval process, animal testing, and gastroparesis issues. Administration of the 21st Century Cares Act (Pub. L. No. 114-255). Administration of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (Pub. L. No. 116-136). COVID-19 Clinical Trials. Agriculture, Rural Development, FDA, and Related Agencies Appropriations for FY2021, provisions regarding FDA testing for new drug applications. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2020-07-16T12:41:24.497000-04:00
2468585 KOUNTOUPES DENHAM CARR & REID, LLC 7d989835-62aa-4d8a-bf8f-84be3cfaaa5a Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2020 second_quarter PHA General information about the company and the industry. Issues related to affordability and pricing of pharmaceuticals. Issues related to the implementation of H.R. 748, Coronavirus Aid, Relief, and Economic Security Act (CARES Act), including drug supply chain dynamics. H.R. 6800, the HEROES Act. Issues related to the federal response to the COVID-19 pandemic. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-16T13:19:31.067000-04:00
2468663 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM c7bfa499-17d8-4956-8e92-c76780639b35 Q2 ATRIUM HEALTH-FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 58534 ATRIUM HEALTH - FORMERLY KNOWN AS CAROLINAS HEALTHCARE SYSTEM 2020 second_quarter PHA Opposition to any provision in any bill to reduce the scope and use of the 340B Drug Discount benefit; HR 4710 340B PAUSE Act Any provision(s) reducing or changing the 340B Drug Discount Program or benefits to hospitals limiting hospital access to the benefit and or improving or updating the program's guidelines. H.R. 3. Lower Prescription Drug Costs Now Act - legislation that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   5987 0 0 2020-07-16T13:37:53.657000-04:00
2468854 KOUNTOUPES DENHAM CARR & REID, LLC 78f5e830-9a3d-4c31-be85-3b3371bf219b Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 BLOOD CANCER UNITED (FORMERLY REPORTED ASTHE LEUKEMIA AND LYMPHOMA SOCIETY) 2020 second_quarter PHA Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2020-07-16T14:19:54.790000-04:00
2469290 TARPLIN, DOWNS & YOUNG, LLC 903c4911-dfa2-45da-8cb4-5e6ea1e11711 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 ASTRAZENECA 2020 second_quarter PHA Drug coverage & reimbursement no specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 1895 - Lower Health Care Costs Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-16T15:33:59.117000-04:00
2469329 BURRELL INTERNATIONAL GROUP LLC d95d9aaa-b269-4f6a-b359-3f5b63aa3139 Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2020 second_quarter PHA No specific legislative vehicles. Issues are, generally, orphan drug legislation, rare disease legislation, drug pricing policy HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2020-07-16T15:42:11.010000-04:00
2469332 340B HEALTH 6074ba7b-2153-42b8-9219-7f5c35b3cc67 Q2 340B HEALTH 316434 340B HEALTH 2020 second_quarter PHA The 340B Drug Pricing Program; FY 2021 L-HHS Appropriations; H.R. 3, Lower Drug Costs Now Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019; H.R. 5281, Drug Price Transparency in Medicaid Act of 2019; H.R.6074, Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020; H.R.6201, Families First Coronavirus Response Act; H.R.748, CARES Act; HR 19, Lower Costs, More Cures Act of 2019 Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   273761 0 0 2020-07-16T15:42:12.893000-04:00
2469347 CAPITOL COUNSEL LLC e1cc85e2-986f-47a0-824d-b1f7ac0d6080 Q2 CAPITOL COUNSEL LLC 313715 VERTEX PHARMACEUTICALS INCORPORATED 2020 second_quarter PHA Monitoring and advocacy on matters related to the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-07-16T15:44:18.950000-04:00
2469491 TARPLIN, DOWNS & YOUNG, LLC 51d966c5-aefa-4769-aad1-e1f595df9924 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.) 2020 second_quarter PHA Importation of prescription drugs (H.R. 447, H.R. 478, H.R. 1478, S. 61, S. 97, S. 658, S. 844) Opioid Abuse - General issues related to opioid drug abuse (Implementation of Public Law 115-271) Implementation of Public Law 113-54 (DSCSA) Issues Related to ARCOS data and suspicious order record requirements & reporting Block, Report, and Suspend Suspicious Shipments Act of 2019 (H.R. 3878) Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2020-07-16T16:09:59.097000-04:00
2469546 BLUECROSS BLUESHIELD OF TENNESSEE b7daf880-bcf4-42b0-b420-31a8d2d6e3cf Q2 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2020 second_quarter PHA Opioid and prescription drug pricing issues; Rx drug rebates; regulation of pharmacy benefit managers; CREATES Act;. H.R.3 - 116th Congress (2019-2020) Lower Drug Costs Now Act of 2019 HOUSE OF REPRESENTATIVES,SENATE   25000 0 0 2020-07-16T16:19:12.743000-04:00
2470411 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) cf5b2a53-dc52-4c1b-9105-538c7f7841bc Q2 HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA) 28776 HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA) 2020 second_quarter PHA Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271) Issues related to ARCOS data and suspicious order record requirements and reporting Importation of Prescription Drugs (HR 447, HR 478, HR 1478, S 61, S 97, S 658, S 844, Public Law 108-173) Implementation of Public Law 113-54 (DSCSA) Block, Report, And Suspend Suspicious Shipments Act of 2019 (HR 3878) Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   334536 0 0 2020-07-17T08:55:45.857000-04:00
2470504 FAEGRE DRINKER BIDDLE & REATH LLP 1d148a5e-a5a5-4994-beb1-d957624506c3 Q2 FAEGRE DRINKER BIDDLE & REATH LLP 12631 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) 2020 second_quarter PHA Illicit prescription drug sales online; rouge internet drug sellers; dangers of counterfeit medicines; risks of drug importation on patient safety; domain name system accountability regarding COVID-19 frauds; WHOIS Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 70000   0 0 2020-07-17T09:20:08.173000-04:00
2470520 FAEGRE DRINKER BIDDLE & REATH LLP ed995da5-1e49-430b-8de7-d15e1397135d Q2 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2020 second_quarter PHA Medication safety, pharmacy regulation, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 110000   0 0 2020-07-17T09:25:12.707000-04:00
2470641 MR. VINCENT A. PANVINI 13c3ddb2-8dc3-46c5-a7ec-68814f318b0f Q2 MR. VINCENT A. PANVINI 401008845 PHRMA 2020 second_quarter PHA Position on Price Controls; patent Protections, Importation of Biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE     0 0 2020-07-17T09:57:38.823000-04:00
2470790 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 525d8eae-7551-4d9d-a14b-0eae5ad905da Q2 MCGUIREWOODS CONSULTING (A SUBSIDIARY OF MCGUIREWOODS LLP) 24486 AMAZON.COM 2020 second_quarter PHA Drug pricing & transparency Federal Aviation Administration (FAA),HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT) 60000   0 0 2020-07-17T10:26:15.187000-04:00
2470934 VAN SCOYOC ASSOCIATES e6951ffd-d508-4153-b022-8afb63f21c31 Q2 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2020 second_quarter PHA Public Law 113-54, Drug Quality and Security Act, Drug labeling implementation Temperature monitoring technology for COVID-19 vaccines HOUSE OF REPRESENTATIVES 30000   0 0 2020-07-17T10:45:41.817000-04:00
2470982 TARPLIN, DOWNS & YOUNG, LLC 53638916-aa3f-4a4c-9416-a79542824cf2 Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 BIOTECHNOLOGY INDUSTRY ORGANIZATION 2020 second_quarter PHA H.R. 1781 - Payment Commission Data Act of 2019 H.R. 938 - the BLOCKING Act of 2019 H.R. 1520 - the Purple Book Continuity Act of 2019 H.R. 1503 - the Orange Book Transparency Act of 2019 H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 H.R. 965 - the CREATES Act of 2019 S. 1895 - Lower Health Care Costs Act S. 1416 - Affordable Prescriptions For Patients Act of 2019 H.R. 3 - Lower Drug Costs Now Act S. 2543 - Prescription Drug Pricing Reduction Act S. 3013 - Encouraging Innovative Benefit Design to Lower Costs for Seniors Act S. 3129 - Lower Costs, More Cures Act of 2019 no specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE 80000   0 0 2020-07-17T10:58:55.060000-04:00
2470995 FAEGRE DRINKER BIDDLE & REATH LLP 0d467441-7536-4e71-80d8-d73ae1ab4b10 2A FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2020 second_quarter PHA Medication safety, pharmacy regulation, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE     0 0 2020-07-17T11:01:58.223000-04:00
2471012 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. fbad7239-e33e-41a4-b0f4-bd3414d5d732 Q2 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2020 second_quarter PHA Opioids; CREATES Act; Drug Pricing HR 4712 (116th Congress), Fairness in Orphan Drug Exclusivity Act, by Rep. Madeleine Dean (D-PA). Amend the Federal Food, Drug, and Cosmetic Act with respect to limitations on exclusive approval or licensure of orphan drugs. HR 5578 (116th Congress), Recall Unsafe Drugs Act of 2020, by Rep. Rosa DeLauro (D-CT). Provide for the mandatory recall of drugs regulated by the Food and Drug Administration. HR 5663 (116th Congress), Safeguarding Therapeutics Act, by Rep. Brett Guthrie (R-KY). Give authority to the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to destroy counterfeit devices. HR 5691 (116th Congress), Insulin Affordability Data Collection Act, by Rep. Angie Craig (D-MN). Require the Secretary to conduct a study and issue a report on the affordability of insulin. HR 5749 (116th Congress), Affordable Insulin for All Act, by Rep. Charlie Crist (D-FL). Establish the American Insulin Program to provide for lower prices for insulin drugs, to maintain effort throughout the insulin supply chain. HR 5894 (116th Congress), Transparency in Prescription Drug Advertising Act, by Rep. Sharice Davids (D-KS). Directs the Secretary of Health and Human Services to issue guidance requiring the list prices of drugs to be included in advertisements for such drugs. HR 5927 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on unsafe Chinese pharmaceuticals and to empower the Food and Drug Administration to mandate drug recalls in the case of critical contamination. HR 5982 (116th Congress), Safe Medicine Act, by Rep. Bill Posey (R-FL). Directs the Secretary of Health and Human Services to study American dependence on Chinese pharmaceuticals and to empower the Food and Drug Administration to issue boxed warnings in the case of critical contamination. HR 6193 (116th Congress), Medication Access in Emergencies Act of 2020, by Rep. Chris Pappas (D-NH). R… Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office   350000 0 0 2020-07-17T11:08:04.047000-04:00
2471162 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 87cc0a13-3144-467f-9bc6-9aa6978ab981 Q2 OLSSON, FRANK, WEEDA, TERMAN & MATZ, PC 30212 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2020 second_quarter PHA Drug pricing, Direct and Indirect remuneration fees, Medicare, COVID-19 Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2020-07-17T11:29:40.020000-04:00
2471397 CENTER FOR INDIVIDUAL FREEDOM 1b59552e-253f-4791-b4c5-4997b870c586 Q2 CENTER FOR INDIVIDUAL FREEDOM 63952 CENTER FOR INDIVIDUAL FREEDOM 2020 second_quarter PHA Buy American Pharmaceutical Mandate Correspondence with White House, United States Senate and United States House of Representatives in opposition to any legislation or executive order imposing Buy American mandates upon pharmaceutical production or procurement; research relating thereto. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of,White House Office   10000 0 0 2020-07-17T12:04:45.667000-04:00
2471435 UNIVERSITY OF IOWA c393b01b-01b8-4aac-b7e8-70bf9a997b25 Q2 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2020 second_quarter PHA N/A Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE   70000 0 0 2020-07-17T12:07:48.827000-04:00
2471494 ACG ADVOCACY fd7268f0-0989-42ab-93b8-f73ccd64b51e Q2 ACG ADVOCACY 2057 WALGREEN CO. 2020 second_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. Public Health Crisis. H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 50000   0 0 2020-07-17T12:13:02.557000-04:00
2471605 ACG ADVOCACY b2b63435-485b-4330-8f6b-83ab581ec6e4 Q2 ACG ADVOCACY 2057 GENENTECH INC 2020 second_quarter PHA Drug Pricing Issues. Public Health Crisis. H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security Act or the CARES Act. Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE,White House Office 40000   0 0 2020-07-17T12:27:37.973000-04:00
2471694 MCDERMOTT+ LLC 1dd43867-19bf-491f-8e32-f2bdd6d5d93b Q2 MCDERMOTT+ LLC 401103287 CAMPAIGN FOR SUSTAINABLE DRUG PRICING 2020 second_quarter PHA S. 1895 - Lower Health Care Costs Act S. 2543 - Prescription Drug Pricing Reduction Act of 2019 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2020-07-17T12:34:01.690000-04:00
2472366 TARPLIN, DOWNS & YOUNG, LLC 9d7a16b8-d63a-4300-8539-8167875bfded Q2 TARPLIN, DOWNS & YOUNG, LLC 304736 NOVO NORDISK INC. 2020 second_quarter PHA H.R. 1520 Purple Book Continuity Act of 2019; H.R. 1503 Orange Book Transparency Act of 2019; issues related to importation; issues related to 340B; H.R. 4244 MAGIC (Market Access for Generic Insulin Competition) Act to provide for a pathway for chemically synthesized insulin to be approved under an abbreviated new drug application submitted under the Federal Food, Drug, and Cosmetic Act) Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE 60000   0 0 2020-07-17T13:58:59.297000-04:00
2472653 KING & SPALDING LLP 5552821e-1ea2-44ea-892f-6702e326aa00 Q2 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2020 second_quarter PHA Issues related to drug pricing and six protected classes HOUSE OF REPRESENTATIVES 60000   0 0 2020-07-17T14:33:08.243000-04:00
2472883 BANNER PUBLIC AFFAIRS, LLC 84b0cd60-36cc-47c6-bbb6-637bec61e2bd Q2 BANNER PUBLIC AFFAIRS, LLC 401046942 THE CIGNA GROUP AND SUBSIDIARIES (FKA CIGNA CORPORATION AND SUBSIDIARIES) 2020 second_quarter PHA Prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-07-17T14:54:07.613000-04:00
2473003 GOVERNMENT COUNSEL, LLC 0dbc8786-099d-4ff8-8e6c-9cb045a9c069 Q2 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2020 second_quarter PHA Issues related to ARCOS data and suspicious order record requirements and reporting (S.3070-Preventing Pill Mills Through Data Sharing Act, S. 2686 & H.R. 4814-Suspicious Order Identification Act of 2019, H.R. 3878-Block, Report And Suspend Suspicious Shipments Act of 2020);implementation of Public Law 113-54 (DSCSA). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2020-07-17T15:03:34.997000-04:00
2473522 E3 STRATEGIC CONSULTING GROUP 4f33e2ee-684e-45a0-946f-b3c3fde16ea0 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) 2020 second_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally; H.R.1425 - Patient Protection and Affordable Care Enhancement Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-07-17T15:42:54.223000-04:00
2473527 E3 STRATEGIC CONSULTING GROUP f8421604-c57a-49cb-b7ab-7a1316d58b95 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2020 second_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally; H.R.1425 - Patient Protection and Affordable Care Enhancement Act HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2020-07-17T15:43:57.160000-04:00
2474049 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 0d055890-7798-4ef6-bdaa-c2367bd44819 Q2 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 2321 AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES 2020 second_quarter PHA HR 1425- The Patient Protection and Health Care Enhancement Act HOUSE OF REPRESENTATIVES,SENATE   660000 0 0 2020-07-17T16:30:06.220000-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2962.002ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API